Getinge (GB:0GZV)
LSE:0GZV
Want to see GB:0GZV full AI Analyst Report?
0GZV Stock Chart & Stats
kr215.37
kr0.56(0.30%)
At close: 4:00 PM EST
kr215.37
kr0.56(0.30%)
Day’s Range― - ―
52-Week Rangekr176.30 - kr230.10
Previous CloseN/A
Volume17.36K
Average Volume (3M)108.58K
Market Cap
kr49.99B
Enterprise Valuekr57.52B
Total Cash (Recent Filing)kr4.02B
Total Debt (Recent Filing)kr10.99B
Price to Earnings (P/E)32.0
Beta0.67
Next Earnings
Jul 16, 2026EPS Estimate
2.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.80
Shares Outstanding254,152,370
10 Day Avg. Volume166,450
30 Day Avg. Volume108,580
Financial Highlights & Ratios
PEG Ratio0.70
Price to Book (P/B)2.03
Price to Sales (P/S)1.70
P/FCF Ratio22.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)11.42
Revenue Forecast (FY)kr34.88B
Bulls Say, Bears Say
Bulls Say
Strong Free Cash Flow GenerationSustained, high-quality free cash flow (3.3B, +25.9% TTM and ~72% conversion) provides durable internal funding for R&D, service expansion, capex and debt reduction. This strengthens financial flexibility and supports long‑term reinvestment independent of short-term revenue swings.
Recurring Service And Consumables RevenueA business model anchored by services, consumables and aftermarket contracts creates repeatable, defenseable revenue tied to installed base. That revenue mix stabilizes cash flows, raises lifetime customer value and supports margin resilience over multi‑year healthcare spending cycles.
Manageable Leverage And Sizable Equity BaseA moderate debt-to-equity (~0.35) and substantial equity provide capacity for targeted investments, M&A or cyclical cushioning. The balance sheet allows strategic action without immediate liquidity strain, supporting durable operations and multi‑year growth initiatives.
Bears Say
Near-term Revenue WeaknessA TTM revenue decline (-2.5%) signals a pause in top-line momentum that can constrain scale benefits and capex returns. If persistent, weaker organic growth limits service attach expansion and reduces the pace at which improved cash flow can translate into higher long‑term profitability.
Rising Debt Versus Prior Years Reduces FlexibilityAlthough leverage is moderate today, the trend of rising debt versus 2021–2023 narrows strategic optionality. Higher indebtedness increases interest and refinancing risk, slowing potential deleveraging and constraining capital allocation during industry investments or acquisition opportunities.
Profitability Below Historical PeaksMargins have improved but remain below prior peaks, reflecting structural cost or mix pressures. Persistently muted operating and net margins limit return on invested capital and reduce the cushion to absorb pricing pressure or higher input costs over the medium term.
Getinge News
0GZV FAQ
What was Getinge’s price range in the past 12 months?
Getinge lowest share price was kr176.30 and its highest was kr230.10 in the past 12 months.
What is Getinge’s market cap?
Getinge’s market cap is kr49.99B.
When is Getinge’s upcoming earnings report date?
Getinge’s upcoming earnings report date is Jul 16, 2026 which is in 74 days.
How were Getinge’s earnings last quarter?
Getinge released its earnings results on Apr 21, 2026. The company reported kr1.8 earnings per share for the quarter, beating the consensus estimate of kr1.633 by kr0.167.
Is Getinge overvalued?
According to Wall Street analysts Getinge’s price is currently Overvalued.
Does Getinge pay dividends?
Getinge does not currently pay dividends.
What is Getinge’s EPS estimate?
Getinge’s EPS estimate is 2.23.
How many shares outstanding does Getinge have?
Getinge has 254,152,370 shares outstanding.
What happened to Getinge’s price movement after its last earnings report?
Getinge reported an EPS of kr1.8 in its last earnings report, beating expectations of kr1.633. Following the earnings report the stock price went up 0.551%.
Which hedge fund is a major shareholder of Getinge?
Currently, no hedge funds are holding shares in GB:0GZV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Getinge
Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers sterile transfer systems, closure processing systems, washers, isolators, sterilizers, logistic automation solutions, bioreactors, bioprocess control systems, bioprocess software, biobundles, bioprocess analytics, and perfusion systems; practice-oriented monitoring systems and disposables, anesthesia machines, beating heart stabilizers and positioners, axius blower mister and coronary shunts, proximal seal systems, ceiling supply units, connected solutions, cleaning and disinfection products, packaging and sealing solutions, monitors and indicators, and SteriTec products. The company also provides thoracic catheters, dry seal chest drain, mobile dry seal drain, dry and wet suction water seal chest drain, and chest drain valves; transitional accessories; endoscope reprocessing; endoscopic vessel harvesting systems; endovascular products; extracorporeal life support or extracorporeal membrane oxygenation products; inspection and packing products; intra-aortic balloon counter pulsation therapies; mechanical ventilation products; medical furniture; modular room systems; operating lights and tables; OR integration and management; patient flow management; patient transport; sterile supply management; sterilization; surgical assist systems; surgical perfusion; transport & storage; trays & baskets; and vascular and cardiothoracic surgery solutions. It offers its products through a network of proprietary sales companies, as well as through agents and distributors in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Getinge AB (publ) was founded in 1904 and is headquartered in Gothenburg, Sweden.
Technical Analysis
Vitrolife AB
―
CellaVision AB
―
Xvivo Perfusion AB
―
Sectra AB Class B
―
Sedana Medical AB
―
Options Prices
Currently, No data available
---